A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Protocol No
NEURO-ROCHE-METEOROID
Phase
III
Summary

This project is being done to compare the effects, good or bad, of satralizumab with placebo alone or in combination with current treatment (baseline/background therapy) on patients with MOGAD.

Description
Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Brain, Spinal Cord, and Nervous System, Multiple Sclerosis
ClinicalTrials.gov
go to website